OVID THERAPEUTICS INC. - COMMON STOCK

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05 фев 2025 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

02 дек 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

12 ноя 2024 08:00:02 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Host Investor Event

31 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

26 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

11 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at Upcoming September Investor Conferences

04 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

13 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

08 авг 2024 08:00:01 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at Upcoming August Investor Conferences

30 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

23 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

10 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

01 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat

17 июн 2024 06:55:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

14 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

04 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

08 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

28 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire